Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | GFER | P55789 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836639 | 0.80 | MEN1 (0.55) | MEN1KMT2AALDH1A1GFERGAA | |
| SCHEMBL25768719 | 0.77 | MEN1 (0.55) | MAPTMEN1KMT2AALDH1A1GFER | |
| SCHEMBL23619042 | 0.77 | MAPK10 (0.55) | MAPTMEN1KMT2AALDH1A1GFER | |
| SCHEMBL6836695 | 0.77 | MAPK10 (0.55) | MAPTMEN1KMT2AALDH1A1GFER | |
| SCHEMBL6836512 | 0.77 | MEN1 (0.68) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL16876450 | 0.76 | TAS2R14 (0.51) | MAPTMEN1KMT2AGFERMAPK10 | |
| SCHEMBL9558899 | 0.76 | KDM4E (0.54) | MAPTMEN1KMT2AALDH1A1GFER | |
| SCHEMBL27618377 | 0.76 | MEN1 (0.46) | MAPTMEN1KMT2AALDH1A1GFER | |
| SCHEMBL3237764 | 0.76 | HDAC1 (0.69) | ALDH1A1GAA | |
| SCHEMBL4943709 | 0.76 | MEN1 (0.73) | MAPTMEN1KMT2AALDH1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533983-B2 | Antiplatelet agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-03 | — | — | US | disclosed |
| EP-2518066-B1 | NOVEL ANTI-PLATELET AGENT | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-20140194407-A1 | NOVEL ANTIPLATELET AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20140194407-A1 | NOVEL ANTIPLATELET AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-10 | — | — | US | disclosed |
| US-8703760-B2 | Antiplatelet agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-8703760-B2 | Antiplatelet agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| EP-2518066-A1 | NOVEL ANTI-PLATELET AGENT | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258951-A1 | NOVEL ANTIPLATELET AGENT | Mitsubishi Tanage Pharma Corporation (JP) | 2012-10-11 | — | — | US | disclosed |
| US-20120258951-A1 | NOVEL ANTIPLATELET AGENT | Mitsubishi Tanage Pharma Corporation (JP) | 2012-10-11 | — | — | US | disclosed |
| US-7939663-B2 | Phosphor metallic compound and an organic electroluminescence device having improved luminous efficiency and color purity; long lifespan; highly efficient phosphor host material | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-05-10 | — | — | US | disclosed |
| US-20080275239-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | SAMSUNG ELECTRONICS CO., LTD., (KR) | 2008-11-06 | — | — | US | disclosed |
| WO-2007078181-A1 | METALLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| US-6713482-B2 | SUCH AS (E)-1-(2-PYRIDYL)-2-STYRYL-1H-BENZIMIDAZOLE; ANTIINFLAMMATORY AND ANALGESIC AGENTS; PROSTAGLANDIN INHIBITORS | PFIZER INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | OKUMURA YOSHIYUKI (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-0937722-B1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6310079-B1 | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2001-10-30 | — | — | US | disclosed |
| EP-0937722-A1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER INC. (US) | 1999-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194407-A1 | NOVEL ANTIPLATELET AGENT | F12, TBXA2R, F11 | MAPT 4876/4885MEN1 2309/4885KMT2A 3462/4885 |
| US-20080275239-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | SCO2, NFE2L2, SOD1 | MAPT 2894/4885MEN1 108/4885KMT2A 1787/4885 |
| US-20120258951-A1 | NOVEL ANTIPLATELET AGENT | F12, TBXA2R, F11 | MAPT 4876/4885MEN1 2309/4885KMT2A 3462/4885 |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | PTGS1, CBR1, CBR3 | MAPT 4772/4885MEN1 4840/4885KMT2A 1611/4885 |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PTGS1, CBR1, CBR3 | MAPT 4736/4885MEN1 4821/4885KMT2A 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.